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Chemokine/chemokine receptor interactions play diverse roles in cell migration and home-
ostasis. Emerging evidence suggests that cancer cells co-opt chemokine networks for
survival, proliferation, immune evasion, and metastasis. Most of the chemokine recep-
tors are reported to be involved in tumor progression. Given their extensive implication in
cancer progression, several chemokine receptor/ligand axes are considered as potential
therapeutic targets. This review provides a survey of chemokine receptor expression in
cancer and evaluates the potential of chemokine receptor imaging as a tool for molecular
characterization of cancer.
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INTRODUCTION
Chemokine/chemokine receptor interactions play key roles in
cell trafﬁcking in host defense mechanisms, in organogenesis,
vasculogenesis, and tissue repair. Most chemokines are secreted
chemotactic cytokines of 8–12 kDa size. They can be divided
into subgroups based on structural and functional characteris-
tics. Structurally, chemokines are classiﬁed into four groups (CXC,
CX3C, XC, and CC) based on the highly conserved ﬁrst two of
the four cysteine residues at the N-terminus (Zlotnik and Yoshie,
2000). Functionally, chemokines are classiﬁed as inﬂammatory or
homeostatic. Inﬂammatory chemokines (e.g.,CXCL8) are induced
by inﬂammatory stimuli to attract polymorphonuclear leukocytes
from the circulation to sites of infection or injury. Homeostatic
chemokines (e.g., CXCL12), on the other hand, are constitutively
expressed and regulate cell trafﬁcking and homing during devel-
opment and immune surveillance. The 48 known chemokines
function by activating the 19 identiﬁed cell surface receptors that
are seven-transmembrane-spanning proteins of the G-protein-
coupled receptor (GPCR) superfamily. The chemokine receptor
nomenclature system is based upon the chemokine subclass speci-
ﬁcity of the receptor,whereby L (ligand) is replaced by R (receptor;
Murphy et al., 2000). Although 6 of the 20 receptors are known to
bind to a single ligand, several of the chemokines/receptors exhibit
promiscuity and bind to more than one receptor/ligand, usually
belonging to a single subclass (Zlotnik, 2006). Since the ﬁrst report
on the involvement of chemokine receptors inmetastasis byMuller
et al. (2001), signiﬁcant progress has been made in deciphering
their roles in cancer. More than half of the chemokine receptors
are implicated in the biology of tumor growth and metastasis. A
growing body of literature suggests that most chemokine recep-
tors, as shown in Table 1, including CXCR2, CXCR3, CXCR4,
CXCR7, and CCR7 play key roles in cancer cell survival, prolif-
eration, homing, adhesion, tumor angiogenesis, and resistance to
conventional and targeted therapies. Several chemokine networks
are now considered potential therapeutic targets for cancer. This
review focuses on the expression of several chemokine receptors
for which there exists signiﬁcant evidence in support of their roles
in tumor biology and their possible uses as diagnostic markers.
CXCR1 AND CXCR2
CXCR1 and CXCR2 show 77% homology and considerable struc-
tural similarity but have distinct ligand-binding pharmacology
(Holmes et al., 1991). CXCR1binds toCXCL6 andCXCL8.CXCR2
binds several chemokines: CXCL1, CXCL2, CXCL3 (GROα, β,
and γ), CXCL5 (ENA-78), CXCL6 (GCP2), CXCL7 (NAP2), and
CXCL8 (Ahuja and Murphy, 1996; Wolf et al., 1998). In the
hematopoietic system, both receptors are expressed on granulo-
cytes, monocytes, and mast cells and on some CD8+ T cells and
CD56+natural killer (NK) cells (Chuntharapai et al., 1994). Func-
tional effects of both the receptors are well characterized for the
binding of the inﬂammatory ligand CXCL8 (IL8) than any other
ligand (Waugh andWilson, 2008). CXCR1 binds only CXCL8 with
high afﬁnity, whereas CXCR2 is known to bind all the ligands with
high afﬁnity (Waugh and Wilson, 2008).
Both receptors have been shown to play important roles in
tumor progression in several cancers. In melanoma, CXCR1 is
ubiquitously expressed on tumor cells at all Clark levels how-
ever, high levels of CXCR2 expression were observed mostly in
high-grade melanomas (Varney et al., 2006; Singh et al., 2009a).
Elevated CXCR2 and CXCL8 expression are correlated with high
microvessel density, tumor angiogenesis, and metastases (Varney
et al., 2006). CXCL8 is also constitutively secreted predominantly
by melanoma cells resulting in an autocrine stimulation of cancer
cells promoting survival, proliferation, and migratory capabili-
ties (Singh et al., 2010). In advanced prostate cancer specimens,
CXCR1, CXCR2, and CXCL8 expression were found to localize
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Table 1 | Chemokine receptor expression in cancer.
Receptor Ligand Known physiological function.
Adopted from Murphy et al. (2000) and
Murphy (2002)
Tumor expression Reference
CXCR1 CXCL6, CXCL8 Neutrophil migration; innate immunity;
acute inﬂammation
Melanoma, prostate, breast Varney et al. (2006),
Shamaladevi et al. (2009)
CXCR2 CXCL1, CXCL2, CXC3,
CXC5, CXCL6, CXCL7,
CXCL8
Neutrophil migration; innate immunity;
acute inﬂammation; angiogenesis
Melanoma, pancreatic cancer,
ovarian, prostate, lung
Singh et al. (2009b,c), Ijichi
et al. (2011), Keane et al.
(2004)
CXCR3 CXCL9, CXCL10,
CXCL11
T cell migration; adaptive immunity;
Th1 inﬂammation
Breast, colorectal, melanoma,
acute lymphocytic leukemia,
B-cell chronic lymphocytic
leukemia
Kawada et al. (2004, 2007),
Ma et al. (2009), Kawada and
Taketo (2011)
CXCR4 CXCL12 B-cell lymphopoiesis; bone marrow
myelopoiesis; central nervous system
and vascular development
23 Different cancers including
breast, prostate, melanoma
etc.
Cabioglu et al. (2005),
Salvucci et al. (2006), Scala
et al. (2005), Sun et al. (2003),
Wong and Korz (2008), Burger
and Kipps (2006), Teicher and
Fricker (2010)
CXCR5 CXCL13 B-cell trafﬁcking; lymphoid
development
Head and neck Muller et al. (2006)
CXCR6 CXCL16 T cell migration Prostate Deng et al. (2010)
CXCR7 CXCL12 Cardiac development Breast, lung, prostate Duda et al. (2011), Miao et al.
(2007), Wang et al. (2008)
CCR1 CCL3, CCL5, CCL7,
CCL8, CCL13, CCL14,
CCL15, 16, CCL23
T cell and monocyte migration; innate
and adaptive immunity; inﬂammation
Colorectal, multiple myeloma Vallet and Anderson (2011)
CCR2 CCL2, CCL7, CCL8,
CCL13
T cell and monocyte migration; innate
and adaptive immunity; Th1
inﬂammation
Multiple myeloma, prostate,
Breast
Loberg et al. (2007), Lu et al.
(2007), Lu and Kang (2009)
CCR3 CCL5, CCL7; CCL8;
CCL11, CCL13;
CCL15; CCL24; CCL26
Eosinophil, basophil, andT cell
migration; allergic inﬂammation
Renal cell carcinoma,
glioblastoma, cutaneousT-cell
lymphoma (CTCL)
Johrer et al. (2005), Kleinhans
et al. (2003), Kouno et al.
(2004)
CCR4 CCL17, CCL22 T cell and monocyte migration; allergic
inﬂammation
Breast, adult T-cell
leukemia/lymphoma, CTCL
Ishida et al. (2003), Li et al.
(2012)
CCR5 CCL3; CCL4; CCL5;
CCL8, CCL14
T cell and monocyte migration; innate
and adaptive immunity
Breast, prostate, glioblastoma Kouno et al. (2004), Vaday
et al. (2006)
CCR6 CCL20 Dendritic cell migration Colorectal, pancreatic,
multiple myeloma
Rubie et al. (2006, 2010)
CCR7 CCL19, CCL21 T cell and dendritic cell migration;
lymphoid development; primary
immune response
Breast, melanoma, NSCLC,
gastric, cervical, stomach,
colorectal, CLL,
non-Hodgkin’s lymphoma, T
cell leukemia
Cabioglu et al. (2005),
Takanami (2003), Mashino
et al. (2002), Ding et al.
(2003), Wiley et al. (2001),
Arigami et al. (2009), Kodama
et al. (2007), Schimanski et al.
(2005)
CCR8 CCL1, CCL4; CCL17 T cell trafﬁcking Kaposi sarcoma Haque et al. (2001)
CCR9 CCL25 T cell homing to gut Melanoma, prostate, ovarian,
breast
Singh et al. (2004, 2011),
Johnson-Holiday et al. (2011)
CCR10 CCl26, CCL27, CCL28 T cell homing to skin Melanoma (immune escape) Murakami et al. (2003)
CX3CR1 CX3CL1 T cell and NK cell trafﬁcking and
adhesion; innate and adaptive
immunity; Th1 inﬂammation
Neuroblastoma, prostate Rodero et al. (2008), Shulby
et al. (2004)
XCR1 XCL1, XCL2 T cell trafﬁcking Moser et al. (2004)
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to cytoplasm, and silencing of CXCR1 has been shown to inhibit
androgen-independent prostate cancer growth (Shamaladevi et al.,
2009). Similarly, CXCR2 has been shown to promote ovarian can-
cer through dysregulated cell cycle proteins p21 (waf1/cip1), cyclin
D1, CDK6, CDK4, cyclin A, and cyclin B1, diminishing apoptosis
by suppressing p53 and poly(ADP-ribose) polymerase cleavage,
and enhancing angiogenesis by increasing levels of VEGF. CXCR2
expression in high-grade serous ovarian carcinoma was also found
to be an independent prognostic factor of poor overall survival and
of early relapse in cancer patients (Yang et al., 2010). Furthermore,
CXCR1 and CXCR2 overexpression has been shown to increase
cancer cell survival in response to hypoxia (Maxwell et al., 2007),
and to promote tumor angiogenesis in renal cell carcinoma (Mes-
tas et al., 2005). Not surprisingly, neutralizing antibodies and low
molecular weight antagonists targeting these receptors as well as
siRNA based downregulation of the receptor expression have been
effective in inhibiting tumor growth and invasion in lung, ovar-
ian, pancreatic, and melanoma tumor models (Singh et al., 2009b;
Ijichi et al., 2011).
In addition to the cancer cells, activated neutrophils express
high levels of CXCR1 and CXCR2 and accumulate at the site of
infection and inﬂammation. This neutrophil accumulation was
monitored non-invasively using 99mTc labeled CXCL8 andCXCL7
proteins in different models of infection (Rennen et al., 2004).
Despite the availability of a variety of monoclonal antibodies
(mAbs) and small molecule structural motifs (Busch-Petersen,
2006) that can be radiolabeled, imaging studies using these agents
in cancer have not yet been reported.
CXCR3
CXCR3 binds CXCL9, CXCL10, and CXCL11 with high afﬁnity,
and is expressed by the Th1T cells, cytotoxic CD8+T cells,Kupffer
cells, endothelial cells, and activated B and NK cells (Garcia-Lopez
et al., 2001). CXCR3 expression directs the migration of these cells
to inﬂamed lymph nodes (LN) and other inﬂamed sites (Liu et al.,
2005).
Nearly one third of melanoma (Kawada et al., 2004) and colon
cancers (Kawada et al., 2007) and most of all of the breast can-
cer specimens tested, though to a different degree, were shown
to be positive for CXCR3 (Ma et al., 2009). CXCR3 expression in
breast and colon cancers and melanoma has been correlated with
LN metastases, and considered an independent predictor of poor
prognosis (Ma et al., 2009; Kawada and Taketo, 2011). Further-
more, colon cancer patients with tumors positive for both CXCR3
and CXCR4 had a signiﬁcantly poorer prognosis than those with
tumors positive only for CXCR4 or the double negatives, under-
scoring the importance of evaluating multiple receptors simulta-
neously (Kawada and Taketo, 2011). In spite of high expression
on tumor cells, downregulation of CXCR3 by siRNA, or inhibi-
tion by low molecular weight agents was not shown to have an
effect on breast or melanoma tumor growth but rather inﬂuenced
the metastatic ability of the cancer cells to the lungs and LNs
(Kawada et al., 2004). Because CXCR3 shows a notable expression
on T cells associated with inﬂammatory conditions, such as pso-
riasis, rheumatoid arthritis, diabetes, inﬂammatory bowel disease,
and multiple sclerosis, several antagonists targeting this receptor
have been in clinical development (Wijtmans et al., 2008). CXCR3
expression has not yet been imaged and presents an attractive
target for imaging.
CXCR4
CXCR4 is one of the most studied chemokine receptors. CXCR4
is a co-receptor for HIV entry, plays a pivotal role in mediating
metastasis in a variety of cancers (Tamamura et al., 2006) and
in autoimmune disease. To date, CXCR4 is known to bind only
one endogenous ligand, CXCL12 (Zlotnik et al., 2006). CXCL12
expression is ubiquitous and it is highly secreted by stromal cells in
lungs, liver, brain, bone marrow, and LNs. CXCR4 is expressed in
several tissues (Gupta andPillarisetti, 1999). TheCXCR4–CXCL12
axis is also distinct frommanyother chemokine networks due to its
role in hematopoiesis, organogenesis, and vascularization. CXCR4
or CXCL12 knock-out mice have defects in B-cell lymphopoiesis,
bone marrow colonization, and cardiac septum formation result-
ing in late gestational lethality (Nagasawa et al., 1996; Tachibana
et al., 1998).
CXCR4 is over-expressed in nearly 20 types of cancer including
breast, brain, lung, ovarian, colon, prostate, and melanoma (Balk-
will, 2004). CXCR4 expression in tumor cells is markedly higher
compared to many normal tissues (Cabioglu et al., 2009; Duda
et al., 2011) and CXCR4 expression is regulated by many tumor-
associated factors: at the transcriptional level by hypoxia, NFκB,
andYinYang 1; at the translational level by HER-2; and at the post-
translational level by E3 ubiquitin ligase and HER-2 (Luker and
Luker, 2006). ElevatedCXCR4 expression in tumors has been asso-
ciated with an aggressive phenotype (Cabioglu et al., 2005; Kang
et al., 2005; Kim et al., 2005). Overexpression of CXCR4 in primary
tumors is directly correlated to increased risk for local recurrence,
distant metastasis, and poor survival rates in breast, colon, and
several other cancers (Cabioglu et al., 2005; Kim et al., 2005; Scala
et al., 2005; Luker and Luker, 2006; Salvucci et al., 2006). In addi-
tion to primary tumors, metastases frequently exhibit increased
CXCR4 expression, which may offer a new strategy for their early
detection (Sun et al., 2003; Salvucci et al., 2006). The hypothesis
is that CXCR4 expression enables tumor cells to home to organs
expressing abundant levels of CXCL12 such as lungs, liver, brain,
and bone marrow leading to establishment of metastases. Neu-
tralizing CXCR4 chemotaxis using low molecular weight agents,
peptides, antibodies, or biological agents such as siRNA, reduces
the migratory capacity of cancer cells in vitro and metastatic bur-
den in vivo in preclinical models (Liang et al., 2004; Smith et al.,
2004; Wong and Korz, 2008).
In addition to the regular GPCR signaling-based activation
of multiple downstream targets, the CXCR4–CXL12 axis is also
known to be involved in several other pathways. It can transac-
tivate HER-2 receptor (Li et al., 2004; Luker and Luker, 2006)
and mediate estrogen-independent tumorigenesis,metastasis, and
resistance to endocrine therapy (Rhodes et al., 2011). Similarly,
migratory effects induced by epidermal growth factor receptor
and insulin-like growth factor signaling cascades in cancer cells
requires CXCR4 activation (Akekawatchai et al., 2005; Phillips
et al., 2005). Recent studies have also identiﬁed increased expres-
sion of CXCR4 and CXCL12 in cancer-associated ﬁbroblasts
(CAFs). CAFs play an important role in tumorigenesis and are
implicated in neoplastic progression, tumor growth, angiogenesis,
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and metastasis (Orimo and Weinberg, 2006). CXCL12 secreted by
CAFs not only stimulates carcinoma cell growth directly through
the CXCR4 receptor displayed on tumor cells but also recruits
endothelial progenitor cells (EPCs) into tumors, thereby fur-
thering angiogenesis (Kojima et al., 2010). Overall, the CXCR4–
CXCL12 axis plays an active role in tumor resistance to conven-
tional as well as targeted therapies by directly promoting cancer
cell survival, invasion, and cancer stem and/or tumor-initiating
cell phenotype; by recruiting myeloid bone marrow-derived cells
to facilitate tumor recurrence and metastasis indirectly; by pro-
moting angiogenesis directly or in a paracrine manner; and by
providing a metastatic niche for cancer cells in the bone marrow
(Duda et al., 2011).
The CXCR4–CXCL12 axis is considered a therapeutic target for
cancer and several CXCR4 inhibitors are in Phase-I trials (Wong
and Korz, 2008;Duda et al., 2011). In addition to reduced metasta-
tic burden, CXCR4 inhibition has also been shown to synergize
chemotherapies in various tumor models (Redjal et al., 2006; Azab
et al., 2009). As blocking the CXCR4–CXCL12 pathway becomes
a viable strategy to target various solid tumors, considering the
large number of normal functions that are affected by the CXCR4–
CXCL12 axis, development, and evaluation of imaging agents for
tracking this pathway in vivo is critical. CXCR4-based imaging
agents would be beneﬁcial to: (i) evaluate primary tumors for ele-
vated CXCR4 expression and therapeutic intervention; (ii) screen
for secondary metastatic spread to both local and distant sites; and
(iii) for therapeutic monitoring.
CXCR4-based imaging agents. Antibodies, peptides, and low
molecular weight agents have been used for molecular imaging
of CXCR4 expression in tumors.
Monoclonal antibodies are re-gaining attention as radiophar-
maceutical imaging agents. To investigate the feasibility of CXCR4-
based imaging,our group radiolabeled awell-characterizedmono-
clonal mouse anti-human CXCR4 antibody, 12G5,with 125I. 12G5
recognizes a determinant in the ﬁrst and second extracellular loops
of CXCR4 and its speciﬁcity to CXCR4 is well established (Barib-
aud et al., 2001). Single Photon Emission Computed Tomography
(SPECT) imaging and biodistribution data showed clear accumu-
lation of [125I]12G5 in the tumors compared to isotype matched
[125I]IgG2A control antibody. Even though the highest accumula-
tion of radioactivity was seen in the spleen and high non-speciﬁc
uptake was observed due to the murine antibody background,
these results establish the feasibility of using radiolabeled mAbs
for imaging CXCR4 expression in tumors (Nimmagadda et al.,
2009).
CXCR4 is characterized by a strong negatively charged extra-
cellular surface, therefore most of the CXCR4 binding agents
are highly basic and positively charged. A detailed overview of
the available CXCR4 binding agents and CXCR4-based imaging
agents can be found elsewhere in the literature (Mosley et al.,
2009; Woodard and Nimmagadda, 2011). The majority of the
CXCR4 targeted imaging agents to date have originated from the
polyphemusin-based peptides and cyclam-based low molecular
weight agents.
The polyphemusin-based peptide T140 provides the foun-
dation for most of the peptide-based CXCR4 imaging agents.
T140 is a 14-residue peptide with a disulﬁde bridge (T140)
and a potent CXCR4 antagonist (Tamamura et al., 1998). Stud-
ies have shown that four aminoacid residues, Arg2, l-3-(2-
naphthyl)alanine (Nal)3, Tyr5, and Arg14, in T140 are critical for
CXCR4 binding (Tamamura et al., 2000). Like many unprotected
peptides, T140 was found to be unstable in serum. To improve
the stability, many CXCR4 selective analogs, including those with
modiﬁcations at each terminus, were synthesized (Tamamura
et al., 2006) and labeled with various radionuclides. First within
this category of peptides is Ac-TZ14011 with the carboxyl group
protected via amidation for stability in vivo and a single amino
group (d-Lys8) distant from the pharmacophore allowing for con-
jugation of chelates. Generally, chelation of peptides reduces the
afﬁnity of the peptide for its target. 111In-DTPA conjugation toAc-
TZ14011 resulted in nearly sixfold decrease in afﬁnity to CXCR4.
Also, a 15- to 200-fold increase in uptake was observed in the
liver, kidneys, and spleen (Hanaoka et al., 2006). However, reason-
able accumulation observed within the tumors and radioactivity
uptake values higher than the muscle or blood led to further devel-
opment of these peptides as dual modality imaging agents (Kuil
et al., 2011). Another amidated analog of T140, the N-terminal 4-
ﬂuorobenzoyl protected TN14003, was labeled with 18F using N -
succinimidyl-4-(18)F-ﬂuorobenzoate or with 64Cu through con-
jugation with DOTA on lysine. Studies in mice harboring Chinese
hamster ovarian (CHO) tumor stably expressing CXCR4 showed
that CXCR4-positive tumors were distinguishable from control
tumors, however, co-injection of unlabeled 4-F-TN14003was nec-
essary to see increased radioactivity in the CXCR4-positive tumors
(Jacobson et al., 2010, 2011). Similarly, CXCL12 radiolabeled with
99mTc orwith near-infrared ﬂuorophores demonstrate poor imag-
ing characteristics in vivo, limiting routine use (Misra et al., 2008;
Meincke et al., 2011). Demmer and colleagues, using a highly spe-
ciﬁc cyclic pentapeptide, recently reported interesting data on a
peptide-based imaging agent. The68Ga-DOTA conjugated peptide
showed optimal pharmacokinetics for imaging with 68Ga, i.e., low
liver uptake and faster clearance from the kidneys indicating its
potential for clinical translation (Demmer et al., 2011).
Among agents of lowmolecularweight, the bicyclamAMD3100
was the ﬁrst non-peptide CXCR4 inhibitor to enter clinical trials
and is now used for stem cell mobilization (De Clercq, 2010).
Cyclams have the ability to form strong complexes with tran-
sition metals such as copper and zinc, enabling development
of a radiolabeled analog of AMD3100 and imaging of CXCR4
expression in vivo. Fortuitously, the afﬁnity of AMD3100 increases
by sevenfold when chelated to copper. Jacobson et al. and our
group have investigated copper-64 radiolabeledAMD3100 (Jacob-
son et al., 2009; Nimmagadda et al., 2010; Weiss et al., 2012).
Using subcutaneous U87 brain tumors (∼2%, CXCR4+), U87
tumors stably expressing CXCR4 (>95%)(U87-stb-CXCR4) and
orthotopic MDA-MB-231 (∼10%) and DU4475 (∼90%) breast
cancer xenografts, we have demonstrated the feasibility of imag-
ing graded levels of tumor CXCR4 expression. In these stud-
ies [64Cu]AMD3100-Positron Emission Tomography (PET) dis-
played distinct accumulation of radioactivity in the U87-stb-
CXCR4 and DU4475 tumors at 90min post-injection of the
radiotracer (Nimmagadda et al., 2010). Considerable uptake was
observed in the liver and lymphoid organs. Given that CXCR4 is
expressed on leukocytes,monocytes and in the liver, accumulation
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of radioactivity in these organs, except for the majority of the
uptake in the liver, is due to CXCR4-speciﬁc binding as conﬁrmed
by blocking studies (Nimmagadda et al., 2010). Becausemetastases
often have elevated levels of CXCR4 expression, using an experi-
mental model of lung metastasis derived from breast cancer cells,
we have also demonstrated that [64Cu]AMD3100-PET enables
non-invasive in vivo visualization of metastases (Nimmagadda
et al., 2010).
While [64Cu]AMD3100 shows promise as a PET imag-
ing agent, low afﬁnity for CXCR4 and a scaffold not ﬂexible
for the development of 18F-labeled analogs may limit clinical
use. A second-generation monocyclam-based CXCR4 inhibitor,
AMD3465 (Figure 1), has high afﬁnity (41.7± 1.2 nM), reduced
charge and is smaller in size compared to AMD3100 (Bodart et al.,
2009; De Silva et al., 2011). Utilizing the aforementioned U87
and U87-stb-CXCR4 glioblastoma model, De Silva and colleagues
showed that [64Cu]AMD3465-PET has the highest target selectiv-
ity reported for this class of agents (Figure 1). These results were
further validated in a colon tumor model (De Silva et al., 2011).
More importantly, the pyridine moiety of AMD3465 may allow
structural modiﬁcation for the synthesis of clinically translatable
agents.
CXCR7
Although initially cloned as orphan receptor Receptor Dog cDNA
1 (RDC1) in 1990 (Libert et al., 1990), RDC1 was renamed CXCR7
once the binding of chemokine ligands CXCL11 and CXCL12 was
characterized (Balabanian et al., 2005; Burns et al., 2006). CXCR7
binds toCXCL12 andCXCL11with high and low afﬁnities, respec-
tively and plays a role in scavenging or sequestering CXCL12α
(Thelen and Thelen, 2008). CXCR7 differs from other chemokine
receptors in several ways. TheAsp-Arg-Tyr-Leu-Ala-Ile-Val (DRY-
LAIV) motif at the second intracellular loop of chemokine recep-
tors, required for coupling a chemokine receptor to Gαi-signaling
proteins, is altered in CXCR7and its sensitivity to pertussis toxin
has not been completely characterized (Thelen and Thelen, 2008).
However, similar to other chemokine receptor signaling, CXCR7
stimulation by CXCL12 has been shown to induce the phospho-
rylation of both MAPK and Akt (Miao et al., 2007; Hartmann
et al., 2008). In the hematopoietic system, CXCR7 is expressed by
the neutrophils,monocytes, and B-cells. CXCR7 is required for the
properdevelopmentof theheart,particularly cardiac valves (Sierro
et al., 2007). Even though CXCR7 is poorly expressed in non-
transformed tissues, increased CXCR7 expression was observed in
transformed cells (Burns et al., 2006).
CXCR7 expression on breast, lung, and prostate cancer cells
positively correlates with their proliferation, vascularization, and
metastatic potential (Miao et al., 2007). CXCR7 is highly expressed
on tumor-associated vasculature and not on normal endothe-
lium suggesting a role in tumor angiogenesis (Miao et al., 2007;
Mazzinghi et al., 2008). Blockade of CXCR7 signaling using low
molecular weight agents, antibodies or siRNA results in smaller
tumors and reduced metastatic dissemination in preclinical mod-
els (Miao et al., 2007). CXCR7 expression is also regulated by
CXCR4 suggesting that combined blockade of CXCR4 andCXCR7
may have synergistic therapeutic effects. Imaging agents speciﬁc
for CXCR7 have not been reported even though CXCL12 labeled
with a near-infrared ﬂuorophore has been used recently for in vivo
imaging (Meincke et al., 2011). The availability of mAbs and low
molecular weight agents present an opportunity for imaging this
important target.
CCR7
Of the CC family receptors only CCR7, due to its pivotal role in
directing LN metastasis, will be discussed in this review. CCR7
binds two ligands, CCL21 and CCL19, which are secreted in LNs.
CCR7 is highly expressed by naïve T cells and dendritic cells and
is required for homing these cells to the LNs for initiating an
adaptive immune response (Forster et al., 2008). CCR7 is also one
of the well-characterized receptors with respect to its role in the
formation of secondary lymphoid structures (Muller et al., 2003).
CCR7 has been shown to be over-expressed in several cancers
including breast, non-small cell lung cancer, esophageal, gastric,
and chronic lymphocytic leukemia (Holmes et al., 1991; Muller
et al., 2001; Mashino et al., 2002; Ding et al., 2003; Takanami,
2003; Zlotnik, 2006). CCR7 expression correlates with decreased
survival of patients with colorectal cancer (Gunther et al., 2005).
Unlike CXCR4, CCR7 expression on tumor cells mostly corre-
lates with LN metastasis. Given the role of CCR7 in directing the
lymphocytes to the LNs, this observation suggests the possible
FIGURE 1 | (A) Structure of [64Cu]AMD3465; (B) Surface CXCR4 expression
in U87 and U87-stb-CXCR4 cells by ﬂow cytometry; (C) PET/CT imaging of
CXCR4 expression in subcutaneous brain tumor xenografts with
[64Cu]AMD3465 (De Silva et al., 2011). (D)Tumor-to-muscle, tumor-to-blood,
and tumor-to-tumor ratios from biodistribution studies of [64Cu]AMD3465 in
subcutaneous brain tumor xenografts.
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usurpation of the chemokine receptor pathway by the cancer cells.
Furthermore, it has been shown that transfection of breast and
melanoma cancer cells with CCR7 shifts the metastasis from lung
to LNs (Wiley et al., 2001;Cunninghamet al., 2010).Another study
demonstrated that CCR7 expression in tumors is highly correlated
with the ability to metastasize to the regional LNs and CCR7-
negative tumors were rarely observed in the local LNs (Takanami,
2003). Taken together, these results strongly suggest that CCR7
expression is important in metastasis to the LNs and non-invasive
imaging agents may help in predicting which tumors will metas-
tasize to the LNs. No imaging studies have been reported for this
receptor.
CLINICAL IMPLICATIONS AND FUTURE CHALLENGES
Since the implication of CXCR4 in the metastatic cascade, consid-
erable progress has been made in establishing the role of various
chemokine receptors in tumor biology. The direct involvement
of chemokine receptor/ligand networks in tumor development,
progression, and immune evasion suggests a potential role for
chemokine network based therapeutic agents as adjuvants to exist-
ing therapies. Even though several chemokine targeted agents
are in use, redundancy in chemokine signaling suggests that
receptor-targeted strategies that eliminate redundant functions
of chemokine signaling may have a greater effect than agents
that solely target the effects of chemokines. Conveniently, many
inhibitors of chemokine receptors are also in development for
other diseases, such as multiple sclerosis or rheumatoid arthri-
tis, which could be translated to oncology. Because chemokine
receptors/ligands are expressed on multiple cancer cell types,
effects of the inhibition of these networks should have broad ther-
apeutic application. The broader tissue expression of the receptors
also calls for a continuous evaluation of receptor dynamics within
the tumor microenvironment, which offers exciting opportuni-
ties as well as challenges to the imaging community. Availability
of inhibitors and chemical scaffolds for almost all chemokine
receptors provides a solid ground to focus on the development
of suitable imaging agents. Even though receptor expression, such
as those of CXCR4 and CCR7, is well characterized, there is great
need to characterize expression of other chemokine receptors in
tumors methodically. Another challenge in translating these imag-
ing agents to the clinic is the possibility of low receptor density on
tumor cells that may be lower than the sensitivity of detection of
some of the imaging modalities. This is compounded by the fact
that signiﬁcantly higher expression of the target on immune cells
may act as “sink” for the imaging agent. Some of these concerns
could be evaluated in biologically relevant preclinical models.
As chemokine receptor blocking agents move into the clinic for
targeted cancer therapy, availability of respective imaging agents
will not only improve accuracy and precision of the molecular
characterization of cancer but also that of other diseases.
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